Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor nerve terminals.
(1) We investigated the effects of single- and double-poisoning with tetanus toxin (TeTx), botulinum neurotoxin type A (BoTx A) and botulinum neurotoxin type B (BoTx B) on spontaneous and nerve-evoked quantal transmitter release at motor endplates of the triangularis sterni preparation of the mouse. (2) Inhibitory effects of TeTx and BoTx B on spontaneous and nerve-evoked transmitter release were very similar, except that the action of BoTx B required 500-fold lower concentrations and was less dependent on temperature. BoTx A caused stronger inhibition of quantal release than TeTx or BoTx B, but was comparatively much easier counteracted by 4-aminopyridine (4-AP). (3) In contrast to BoTx A, with TeTx or BoTx B the increase of transmitter release following onset of 50 Hz nerve stimulation was delayed for a few seconds and synaptic latencies of quanta showed large variations. This release pattern was also evident in all double-poisoning experiments, regardless of intoxication sequence. (4) Inhibition of evoked release was found to be slightly stronger with TeTx than with BoTx B, so the amount of nerve-evoked quanta released after double-poisoning with any sequence of these toxins always approached that of TeTx. In no case supra-additive actions were observed. (5) A strong reduction of evoked quanta was observed when BoTx A was applied in addition to either of the two other toxins. With reversed poisoning sequences (BoTx A - TeTx or BoTx A - BoTx B) the resulting values remained at the extremely low level of BoTx A. (6) In the presence of 4-AP double-poisoning with any combination between BoTx A and TeTx or BoTx B (regardless of intoxication sequence) revealed supra-additive effects, since the number of quanta released was considerably lower than that obtained with any of the toxins alone (in the presence of 4-AP). (7) Our results indicate that tetanus toxin and botulinum toxin type B have a common site of action which is different and independent from that of botulinum toxin type A.
D000818:Animals; D001905:Botulinum Toxins / Q000633:toxicity*; D004347:Drug Interactions; D066298:In Vitro Techniques; D051379:Mice; D008959:Models, Neurological; D009045:Motor Endplate / Q000187:drug effects / Q000473:pathology*; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology*; D009469:Neuromuscular Junction / Q000473:pathology*; D018377:Neurotransmitter Agents / Q000378:metabolism; D013744:Tetanus Toxin / Q000633:toxicity*
D018377:Neurotransmitter Agents; D013744:Tetanus Toxin; D001905:Botulinum Toxins